M&A / Deals Autoimmune disease biotech Odyssey sets terms for $225m IPO PharmaphorumAfter abandoning an IPO bid last year, Odyssey is trying again, emboldened by recent big-value listings that suggest 2026 could be a bumper year.Immunology & InflammationRead full story pharminent May 5, 2026 (Last updated: May 5, 2026) Pharmaphorum After abandoning an IPO bid last year, Odyssey is trying again, emboldened by recent big-value listings that suggest 2026 could be a bumper year. Immunology & Inflammation Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Cytospire hauls in $83M for a new type of T cell engagerNext: Latus Bio secures $97m in funding to boost gene therapy access Related Stories M&A / Deals AbbVie climbs post-Allergan M&A peak with Apogee buy pharminent June 22, 2026 M&A / Deals Lilly bets up to $800M for BioArctic’s brain delivery tech pharminent June 22, 2026 M&A / Deals Insilico and SK Bio forge $2.5bn AI neuroimmunity alliance pharminent June 22, 2026
